Is Iron Maintenance Therapy Better Than Load and Hold?

Connie M. Rhee* and Kamyar Kalantar-Zadeh*†‡

*Harold Simmons Center for Kidney Disease Research & Epidemiology, Orange, California; †University of California Irvine Medical Center, Orange, California; and ‡Department of Epidemiology, University of California Los Angeles School of Public Health, Los Angeles, California

doi: 10.1681/ASN.2013050456

The history of intravenous (IV) iron for anemia management in patients undergoing maintenance dialysis makes for a most fascinating, educational, and clinically relevant story. There have been mixed data, strong opinions, and polarized views among different camps and across multiple dimensions.

Nephrologists and hematologists have not yet arrived at a universal front or consensus on several core questions related to iron and anemia management in CKD: (1) Is iron deficiency a major component of anemia of CKD, and, if so, to what extent and at what level of clinical significance, and upon what stage or severity of CKD? (2) Does iron therapy increase hemoglobin levels and improve outcomes in patients with CKD independent of the background cause of anemia, be it erythropoietin or iron deficiency, inflammation-related hyperhepcidinemia, or other hematologic and non-hematologic conditions? (3) What is the best iron agent and what is the optimal strategy for iron therapy in patients with non-dialysis-dependent CKD versus patients receiving long-term dialysis in terms of dose, frequency, and route (oral versus parenteral), and do outcomes differ if iron is administered consistently (i.e., weekly to monthly) versus sporadically, also known as bolus or repletion dosing or “load and hold” (i.e., providing a large amount of iron over a short period when needed)? (4) Does the type of vascular access (catheter versus arteriovenous shunt) or dialysis therapy modality (including peritoneal versus hemodialysis and conventional versus frequent hemodialysis) affect iron store status and the amount of iron loss, and, hence, is the dialysis modality an important determinant of iron therapy dose and frequency? (5) Does iron supplementation improve patients’ quality of life or survival, or does it impart harm by virtue of allergic reactions, oxidative stress, and iron overload? Finally, (6) what are the most reliable tests with which to assess iron status in patients with CKD, including conventional (serum iron, ferritin, and transferrin saturation ratio) versus more novel (content of reticulocyte hemoglobin, zinc protoporphyrin, percentage of hypochromic erythrocytes, hepcidin) iron markers versus elaborate tests (liver scanning and liver and bone marrow biopsy)?

The vast knowledge gap surrounding iron therapy in many ways parallels the uncertainty relating to erythropoietin-stimulating agents (ESAs). Indeed, after more than a quarter of a century of CKD anemia management, we still lack clear consensus on whether increasing hemoglobin levels with ESAs is safe and on whether ESAs improve patient-centered outcomes, even though 10%–25% of the dialysis budget has been expended on the purchase of ESAs over the past two decades. For many years, ESAs were frequently administered without reservation to nearly all dialysis patients, without anyone asking the same questions about safety and effectiveness that we ask about iron. Only recently did ESAs as a class receive a black box warning, with particular restrictions for patients with CKD and cancer, including exceptionally rigorous APPRISE (Assisting Providers and cancer Patients with Risk information for the Safe use of ESAs) program requirements. In contrast, such black box warnings have not yet been applied to the same good (or bad) old iron agents. Nonetheless, many nephrologists and hematologists appear to be consumed by “iron apprehension.”

Whereas the dose and frequency of ESAs in patients undergoing long-term dialysis are not frequently questioned, and although maintenance dosing of ESAs—usually thrice weekly to every other week—is considered standard of care by practicing nephrologists, there appears to be less acceptance of iron administration in the same manner.

There may be several reasons for this “iron apprehension”:

1. A clinical trial performed more than three decades ago in 137 iron-deficient Somalis suggested that risk of infection in those who received iron therapy was almost five times higher than among patients who received placebo. Although this historical study had many limitations and flaws (including small sample size and less clear study design, implementation, and randomization patterns), it has maintained a strong influence on our iron therapy practices even today, such that we still tend to withhold iron therapy at any sign of or concern for infection. In the pre-ESA era, several case reports were published about the risks and consequences of secondary hemochromatosis in anemic dialysis patients as a result of blood transfusions, whereas case reports of iron overload and similar ferritin levels ranging from 5000 to 20,000 ng/ml, implicating IV
iron administration are almost nonexistent. (3) Several in vitro studies have indicated an association between iron supplementation and oxidative stress in cell cultures, but equivalent human data are not convincing. (4) A limited number of observational studies have suggested an association between high serum ferritin and infection or mortality, as well as between iron administration and indices of cardiovascular disease or death risk in dialysis patients, although more recent studies using more sophisticated methods refuted prior associations as confounding. (5) Several recent studies using liver imaging techniques have shown evidence of iron overload in the liver among hemodialysis patients receiving ESA and IV iron, but these data have rarely been confirmed by liver biopsies. In addition, no studies have shown that liver iron in dialysis patients correlates with morbidity or mortality.

Assuming that there may still be reasons to “fear” IV iron therapy, one critical question that has persisted without any clear answer relates to the safest strategy of iron therapy administration. This question is of immediate importance and urgency given the recent drastic increase in IV iron therapy for managing long-term dialysis patients in the bundled-payment era, combined with the emerging and undeniable evidence that ESAs may cause more harm, particularly if administered without adequate iron stores, leading to relative thrombocytosis, platelet activation, and subsequent thromboembolic events and death.

In this issue of JASN, Brookhart et al. examine a contemporary (2004–2008) cohort of approximately 120,000 hemodialysis patients from all DaVita dialysis units across the United States who received 776,203 unique IV iron administrations. They sought to systematically evaluate the association between iron therapy dosing and frequency over 1-month exposure periods with subsequent infectious events (including hospitalization and death) during subsequent 3-month follow-up periods. The investigators specifically compared low (<200 mg per month) versus high (>200 mg per month) IV iron dose, as well as “repletion” (“load-and-hold”) iron therapy (i.e., boluses of a large amount of IV iron, such as 300–1000 mg divided by 3–10 doses over several consecutive hemodialysis treatment sessions, usually over a short period of 1–3 weeks) versus “maintenance” iron therapy (i.e., weekly, biweekly, or monthly administration of small amounts of IV iron, such as 25–100 mg at each administration) to maintain consistent iron administration without any interruption. During the exposure period, more than one third of patients did not receive IV iron, whereas 49% and 12% received maintenance and bolus therapies, respectively. Compared with the maintenance group, patients receiving bolus therapy had 25 additional infection-related hospitalizations per 1000 patient-years during the 3-month follow-up period, whereas maintenance iron therapy was not associated with worse outcomes compared with nontreatment. Bolus iron therapy was also associated with an 11% higher death risk due to infectious diseases compared with maintenance therapy.

Whereas this rigorous study by Brookhart et al. suggests that maintenance iron supplementation in hemodialysis patients is safe and is associated with fewer infection-related hospitalizations and deaths than “load-and-hold” iron administration, the inherent limitations of such an observational study should be acknowledged. In particular, examining the prognostic implications of iron therapy using a nonrandomized design may be fraught by confounding by medical indication, which is often not amenable to multivariate adjustment, even if novel and sophisticated methods are used.

That the risk of bolus iron therapy was highest among hemodialysis patients with a catheter or with recent infections may in fact point to residual confounding. However, in contrast to randomized controlled trials, such large-scale observational studies may allow us to examine treatments administered over longer periods, with more clinically relevant outcomes among populations that are more broadly generalizable.

Notwithstanding the fact that IV iron therapy may lead to allergic reactions, oxidative stress, promotion of bacterial growth, and impairment of host defenses, the decades-old “iron apprehension” among providers in the absence of convincing evidence has become a major handicap in the management of anemia in dialysis patients. The findings by Brookhart et al. are inconsistent with the notion that maintenance IV iron is deleterious by enhancing predisposition to infection or death. Many reports concerning adverse effects of iron in CKD patients are based on in vitro studies without in vivo verification. The belief that gentle iron maintenance therapy causes more harm than the enormous underlying comorbid conditions of uremic patients is probably flawed and may be analogous to fearing harm from the long-term risk of diabetes in a patient with short-term life expectancy due to advanced metastatic cancer. Historically, despite sporadic reports of a possible association between high iron marker levels and poor cardiovascular outcome in the general population, more robust epidemiologic studies did not show an increased risk of coronary heart disease with high iron saturation ratios.

On the contrary, these studies showed a possible association between iron deficiency with all-cause and cardiovascular mortality in the general population. Similarly, recent studies in dialysis patients showed that a low, rather than a high, serum iron level is associated with higher death risk. To date no randomized controlled studies have been conducted to substantiate the risk of increased infection or death as a result of IV iron therapy in dialysis patients. Indeed, evidence indicates that the activity of the proinflammatory cytokine TNF-α can be reduced by IV iron therapy in patients with CKD.

Human bone marrow can be likened to a factory of hemoglobin production; it needs both iron as the raw material and ESA as the labor force. Providing one without the other does not allow for smooth and consistent hemoglobin production,
and may indeed cause harm when both excess iron accumulates and when laborers lack sufficient raw material to work with. Sporadically overloading the labor workers with huge amounts of raw material and then withholding the supply for long intervals does not allow the dysfunctional factory to operate better. The most reasonable approach may be achieved by maintenance therapy, in which we recommend weekly, every-other-week, or, at a minimum, once-per-month administration of IV iron, at 25 mg–100 mg per dose, to any infection-free hemodialysis patient who receives maintenance ESA therapy and whose serum ferritin is <1200 ng/ml.

ACKNOWLEDGMENTS

C.M.R. is supported by a National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) grant (F32 DK093201). K.K.Z. is supported by research grants from the NIH/NIDDK (R01-DK078106, K24-DK091419) and a philanthropist grant (F32 DK093201). K.K.Z. is supported by research grants from the Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) and Vifor. C.M.R. is supported by a National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) grant (K24-DK091419).

DISCLOSURES

Dr. Kalantar has served as a consultant to Amgen, DaVita, Fresenius, Keryx, and Vifor.

REFERENCES